BioLASCO Taiwan Co., Ltd.

6662 · TWO · Healthcare / Biotechnology

28.15TWD-0.25 (-0.88%)

Price History

Full chart

Market Stats

Previous Close28.40

Open28.15

Day Range28.15 – 28.15

52-Week Range26.56 – 31.73

Volume1.01K

Market Cap732.50M

P/E (TTM)17.99

Forward P/E0.00

EPS1.59

Dividend Yield5.42%

Beta0.16

50-Day Avg29.07

200-Day Avg29.66

About

BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory animals in Taiwan and internationally. The company offers lab animals, such as rat, mice, and others, as well as surgical services; and rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system, and experimental equipment. It also offers reagents, including lab animal diagnostic reagent, endotoxin testing system, portable endotoxin testing system, rapid microbial detection, biological indicators, and iReal antibody; and various services, such as animal testing, pathology and toxicology, serological testing, lab animal center management services. BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Yong-Hao Chen
Employees91
HeadquartersNo. 316, Chongyang Rd., Taipei, Taiwan, 115, Taiwan
Websitehttps://www.biolasco.com.tw

Leadership

Mr. Yong-Hao ChenGeneral Manager
Chang BeckFinancial Officer & Accounting Officer
Zhi-Hao ZhangAccounting Supervisor

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	227.58M	235.91M	264.72M	292.50M	262.66M
Growth (%)	-	+3.66%	+12.21%	+10.49%	-10.20%
Cost of Revenue	122.47M	131.43M	160.37M	177.74M	157.89M
Gross Profit	105.11M	104.49M	104.35M	114.76M	104.78M
Gross Margin	46.18%	44.29%	39.42%	39.24%	39.89%
Operating Expense	51.18M	55.22M	53.54M	59.06M	56.66M
Operating Income	53.93M	49.27M	50.81M	55.71M	48.11M
Operating Margin	23.70%	20.88%	19.19%	19.04%	18.32%
EBITDA	-	64.18M	73.86M	67.64M	63.13M
EBITDA Margin	-	27.21%	27.90%	23.13%	24.03%
Net Income	45.15M	42.31M	49.74M	44.03M	42.43M
Net Income Margin	19.84%	17.94%	18.79%	15.05%	16.15%
Interest Expense	877.00K	1.08M	1.30M	1.75M	2.03M
Interest Expense % of Total Revenue	0.39%	0.46%	0.49%	0.60%	0.77%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	574.26M	569.69M	573.14M	612.67M	592.58M
Total Liabilities	113.91M	115.05M	111.98M	163.29M	134.86M
Total Equity	460.36M	454.64M	461.16M	449.38M	457.72M
Cash	201.17M	168.50M	142.97M	106.82M	80.71M
Net Debt	-	-	-	-	10.84M

Cash Flow

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	70.84M	44.69M	29.46M	56.86M	48.71M
Capital Expenditure	4.36M	4.27M	1.63M	55.93M	21.65M
Free Cash Flow	66.49M	40.42M	27.83M	931.00K	27.06M
Dividends Paid	51.23M	40.98M	38.42M	42.26M	38.42M
FCF to OCF	93.85%	90.44%	94.47%	1.64%	55.55%
Dividend Paid to FCF	77.05%	101.39%	138.05%	4539.21%	141.98%

Key Statistics & Ratios

Market Cap732.50M

Enterprise Value675.68M

Trailing P/E17.99

Forward P/E0.00

Price / Sales2.84

Price / Book1.71

EPS1.59

Book Value16.69

Revenue (TTM)258.04M

Gross Profit (TTM)101.69M

EBITDA59.15M

Profit Margin15.85%

Operating Margin17.58%

Return on Equity9.56%

Return on Assets4.74%

Shares Outstanding25.61M

Shares Float15.86M

Beta0.16

Dividend Yield5.42%

Dividend Rate1.55

Payout Ratio94.34%

Dividends

20261×

1.55Aug 7, 2026

20251×

1.50Aug 7, 2025

20241×

1.65Jul 26, 2024

20231×

1.50Aug 16, 2023

20221×

1.60Jul 21, 2022

20211×

2.00Aug 23, 2021

20201×

1.90Jul 16, 2020

20191×

1.85Jul 17, 2019

20181×

1.80Jul 30, 2018

Stock Splits

Jul 30, 20181055:1000